Overview of Available Third-Line Options in mCRC

Panelists discuss the therapeutic landscape for metastatic colorectal cancer once patients progress to third-line treatment. They outline the available agents, including trifluridine/tipiracil (FTD/TPI), regorafenib, and newer targeted therapies, emphasizing how trial data inform their integration into practice.

The RECOURSE trial plays a central role in establishing FTD/TPI as a viable option, with its demonstrated improvements in overall survival and a manageable safety profile. Clinicians highlight how such data provide confidence in recommending therapy beyond standard second-line regimens.

Ultimately, they stress that treatment choice must balance efficacy with tolerability to ensure quality of life for patients already heavily pretreated.